Benefits of Gilead and Janssen HIV drugs 'slight' says German HTA
This article was originally published in Scrip
Executive Summary
Both Gilead's fixed combination HIV drug Eviplera (rilpivirine plus emtricitabin plus tenofovir) and Janssen's single agent Edurant (rilpivirine) offer proof of "slight" additional benefit based on their better safety profile, according to the G-BA, the committee in charge of reimbursement in Germany.